Serotonin syndrome is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine. The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various subtypes of serotonin receptors. There is no e¡ective drug treatment established. The history of the treatment of serotonin syndrome with 5-hydroxytryptamine blocking drugs is reviewed. A literature search was undertaken using both Medline and a manual search of the older literature. Reports of cases treated with the 5-HT 2 blockers cyproheptadine and chlorpromazine were identi¢ed and analysed. There is some evidence suggesting the e¤cacy of chlorpromazine and cyproheptadine in the treatment of serotonin syndrome. The evidence for cyproheptadine is less substantial, perhaps because the dose of cyproheptadine necessary to ensure blockade of brain 5-HT 2 receptors is 20^30 mg, which is higher than that used in the cases reported to date (4^16 mg).
Introduction
Serotonin syndrome (SS) is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine (5-HT). The clinical manifestations are mediated by the action of 5-HT on various subtypes of serotonin receptors. Cases of probable SS found in the literature that were treated with the 5-HT receptor blockers chlorpromazine or cyproheptadine are reviewed. Of all the cases of SS identi®ed, only these were treated with chlorpromazine or cyproheptadine. The response to treatment is estimated from the limited data available in these reports.
There have been about 23 deaths from SS reported in the medical literature in the last 10 years, not including those associated with 3,4-methylenedioxymethamphetamine (MDMA) toxicity (Tackley and Tregaskis, 1987; Brennan et al., 1988; Kline et al., 1989; Stern et al., 1992; Beasley et al., 1993; Neuvonen et al., 1993; Nimmo et al., 1993; Braitberg, 1994; Keltner, 1994; Hernandez et al., 1995; Power et al., 1995) and it is likely that other deaths have occurred about which no account has been published. None of the deaths reported in the literature occurred during the treatment of depressive illness with irreversible monoamine oxidase inhibitors (MAOIs) combined with tricyclic antidepressants (TCAs), i.e. mixed or combined antidepressant treatment. This is probably because the TCAs that exhibit greater serotonin reuptake inhibitor activity, in therapeutic dosages, have rarely been used therapeutically with MAOIs. The most potent serotonin reuptake inhibitors of the TCAs are clomipramine (CMI) and imipramine (IMI) (Richelson, 1984 ) and when they have been combined with MAOIs, in overdose or accidentally, they have often caused SS.
Background
There were reports of SS from animal research starting in 1958 (Bogdanski et al., 1958; Horita and Gogerty, 1958; Hess et al., 1959; Hess and Doepfner, 1961; Himwich and Petersen, 1961; Himwich, 1962; Curzon et al., 1963; Nymark and Moller Neilsen, 1963; Loveless and Maxwell, 1965; Rogers and Thornton, 1969; Penn and Rodgers, 1971; Fahim et al., 1972; Sinclair, 1973; Green and Grahame-Smith, 1976; Jounela et al., 1977; Felner and Waldmeier, 1979; Fjalland, 1979; Marsden and Curzon, 1979) and these continued to accrue until the seminal papers of Marley (Marley and Wozniak, 1983; Marley and Wozniak, 1984a,b; Marley and Wozniak, 1985) , usually without percolating through to the corpus of psychiatric literature. These early studies indicated that some neuroleptics lessen symptoms of SS in animals (Bogdanski et al., 1958; Himwich and Petersen, 1961; Sinclair, 1973; Green and Grahame-Smith, 1974; Marley and Wozniak, 1984b) and that the hyperactivity syndrome which was seen when some analgesics were given in combination with MAOIs was related to excess intra-synaptic 5-HT. Subsequent work has shown that meperidine and dextromethorphan have, in addition to their other properties, serotonin reuptake inhibitor activity (Carlsson et al., 1969; Carlsson and Lindqvist, 1969; Sinclair, 1973) . Many MAOI/analgesic reactions have been recorded in humans and these have occurred only with analgesics that have serotonin reuptake inhibitor activity (Mitchell, 1955; Papp and Benaim, 1958; Palmer, 1960; Shee, 1960; Cocks and PassmoreRowe, 1962; Denton et al., 1962; London and Milne, 1962; Taylor, 1962; Vigran, 1964; Pollock and Watson, 1971; Sovner and Wolfe, 1988; Hansen et al., 1990; Zornberg et al., 1991; Zornberg, 1993; Jahr et al., 1994; Mason and Blackburn, 1997) . Even moclobemide (MOC), a selective reversible inhibitor of MAO-A (RIMA) with a very short half-life, has been implicated in producing SS in therapeutic dosages, both with relatively weaker serotonin reuptake inhibitors such as IMI (Brodribb et al., 1994) , meperidine (Gillman, 1995 ), uoxetine (Benazzi, 1996 Liebenberg and Berk, 1996) , and more potent serotonin reuptake inhibitors such as paroxetine (Robert et al., 1996) . It is likely that the risk of SS with MOC is much lower than with MAOIs.
The present state
There is no established de®nition of the diagnostic features of SS; indeed, it is not a discrete entity with diagnostic features (Hilton et al., 1997; Lane and Baldwin, 1997) . Calling it a syndrome may be misleading in the sense that it is a manifestation of increasing intra-synaptic 5-HT levels to which everyone is liable, not an idiosyncratic response like neuroleptic malignant syndrome (NMS). It may be more relevant and helpful to ascertain the symptoms and signs associated with increasing degrees of severity.
The picture in humans is congruent with that seen in animals given drugs that increase intra-synaptic 5-HT. This is characterized by enhanced locomotor activity, forepaw treading, shivering, tremors, hyperexcitability, dilated pupils, salivation,¯ushing, tachypnoea, hypertension, lateral head weaving, hind limb abduction, arched (straub) tail, pyrexia, myoclonus and seizures (Bogdanski et al., 1958; Himwich and Petersen, 1961; Sinclair, 1973; Marley and Wozniak, 1983) . There is much imprecision in de®nitions of SS; the term`mental status changes' has been used without precise de®nition. Some features are likely to represent different points on a continuum of severity, e.g. poor concentration4memory impairment4confusion4delirium, or various forms of the same basic phenomenon, e.g. clonus, myoclonus, ocular oscillations,`oculo-gyric crisis' and eyes deviated upward. One primary element is the hyperactivity which manifests in mental (agitation, hypomania) and physical (restlessness and hyperactivity) forms. The other key features are hyperre¯exia, hypertonia/rigidity and particularly clonus (inducible, spontaneous and ocular) (Sternbach, 1991; Hilton et al., 1997) . The key features of SS and NMS are contrasted in Table 1 .
Until the 1980s, it was not generally understood that symptoms were related to excessive intra-synaptic concentrations of 5-HT. This hypothesis had, however, been advanced by a neurologist, Oates, in 1960 following observations of symptoms in patients treated with an MAOI and L-tryptophan (Oates and Sjoerdsma, 1960) .
The literature about SS is expanding rapidly; recent reviews summarize the ®eld (Bodner et al., 1995; Lejoyeux et al., 1995; Mills, 1995; Sporer, 1995; Brown et al., 1996; Martin, 1996; Brubacher, 1997; Hilton et al., 1997; Lane and Baldwin, 1997) . However, few reviews have concentrated on treatment and some of the cases reported here have never been analysed.
Methods
Many episodes of SS in the literature, from the late 1950s until the early 1980s, were unrecognized or have been forgotten. The author identi®ed reviews that dealt with`combined treatment' (TCAs and MAOIs) and studied them for any reports that might represent SS (Ayd, 1961a; Bowen, 1964; Gander, 1965; Schuckit et al., 1971; Beaumont, 1973; Sethna, 1974; Ananth and Luchins, 1977; Moller Nielsen, 1980; White and Simpson, 1981; Razani et al., 1983; Lieberman et al., 1985; Clark and Lipton, 1986; Goldberg and Thornton, 1986) . One review considers all drugs which affect body temperature in animals and humans and contains 794 references (Clark and Lipton, 1986) . All the drugs mentioned in the present article that have been implicated in SS were cross-checked for human cases which were then checked to see if they met the clinical criteria for SS. An extensive manual search of the literature before the start of the Medline database revealed numerous reports in humans. A total of 12 reports of possible SS were identi®ed before the end of 1962 (Mitchell, 1955; Papp and Benaim, 1958; Palmer, 1960; Shee, 1960; Ayd, 1961b; Babiak, 1961; Brownlee and Williams, 1961; Harrer, 1961; Howarth, 1961; Clement and Benazon, 1962; Cocks and Passmore-Rowe, 1962; Reid, 1962) . Computer searches using the terms`hyperthermia',`hyperpyrexia',`serotonin syndrome', or`toxic' and`serotonin' and MDMA' were carried out and the resultant abstracts scanned. In addition, reports of NMS were examined to ascertain whether cases had been misclassi®ed. The criteria used in this present paper for assessing whether a case was one of probable SS are in accord with the reports in Table 1 .
The degree of seriousness of symptoms (Table 2) has been classi®ed as mild, moderate or severe as an approximate guide for comparison. Mild signi®es three de®nite symptoms from Table 1 but no requirement for action (e.g. treatment or admission to hospital); moderate signi®es four or more de®nite symptoms from Table 1 which between them cause signi®cant impairment of functioning or make medical observation necessary; severe signi®es that most symptoms from Table 1 are present or signi®cant impairment of consciousness or functioning is present, to an extent mandating hospital care and active treatment. Further research is required to de®ne more precisely the pattern and progression of symptoms. Table 2 summarizes the treatment and estimated response of cases given chlorpromazine and cyproheptadine. In chlorpromazine treated cases (a total of 13) seven episodes were severe and of these there was a good response in three and a poor response in four. The poor response, Ciocatto's case, followed a dose of 10 mg of chlorpromazine (Ciocatto et al., 1972) . Four episodes were rated as being of moderate severity and of these there was a good response in three and moderate response in one. Two cases were rated as mild; these are the previously unreported cases from the present author. They occurred in patients under close observation in a specialist unit and were not unexpected. They were treated at an early stage.
Results
In the cyproheptadine treated cases (a total of seven), none were rated as severe and only three as de®nite SS. Only three out of the seven were of moderate severity and, of these, one response was good, another was moderate and the third was poor. All three de®nite cases involved MAOIs, with one response rated as good, a second as moderate and the third (given a high dose of cyproheptadine) as no response at all. Of the total of seven cases, one did not ful®l criteria for SS and one should be regarded as a`possible', leaving only ®ve as probable or de®nite. Three of these ®ve either had no or a poor response. In only one case was the response rated as good. The improvement, within 30 min of only 4 mg of cyproheptadine, is rapid for oral onset of action and may represent spontaneous resolution.
Discussion
There is great dif®culty in assessing response in such cases where the natural course of the reaction is not known with certainty. The varied nature and circumstances of these reports prevents much useful comparison with other cases not treated with chlorpromazine or cyproheptadine. All the severe cases occurred with MAOIs. The de®nite cases treated with cyproheptadine were of moderate severity and show little indication of improvement, only one was rated as a moderately good response. In the chlorpromazine cases, there is a stronger suggestion of response; in the seven severe cases, three out of seven showed good response. In the four moderately severe cases, three out of four showed good responses and one a moderate response. It is salutary to note from recent reports how rapid (within 2 h) patients' deterioration can be (George and Godleski, 1996; Mathew et al., 1996; Robert et al., 1996) , especially with combinations such as CMI and tranylcypromine (TCP) (Corkeron, 1995; Brubacher et al., 1996; Gillman, 1996) . Both rapidity of onset and severity of symptoms are related to high potency drugs, larger doses and the route of administration (IV 4 IM 4 oral). The duration of the reaction will have some relationship to the elimination half-life which is long with CMI and¯uoxetine (Pato et al., 1991; Coplan and Gorman, 1993) . The old MAOIs bind irreversibly with MAO which may take 2 weeks or more to return to normal levels (Arnett et al., 1987) . SS has been reported up to 4 weeks after ceasing a selective irreversible MAOI (clorgyline) (Insel et al., 1982) . The largest series of fatal reactions documented (seven deaths) was with MAOIs given after¯uoxetine (Beasley et al., 1993) . In these cases, TCP was started between 12 h (case 1), and a few days, after¯uoxetine. These reports illustrate that a thorough knowledge of the potency, pharmacodynamics and pharmacokinetics of drugs is needed to judge the likelihood of reactions in individual cases.
Small changes of dosage of some drugs may markedly increase effects and there is evidence of a ®ne line between sideeffects and toxicity; this was evident in several of the author's cases, especially those involving TCP. Symptoms only developed after the dose had been increased from 20±30 mg per day. This accords with the author's clinical impression from treating many patients with TCP which is that few get an optimal improvement with less than 30 mg per day. One unusual paper reports the side-effects encountered in 45 cases where CMI and TCP were administered together (Oefele et al., 1986) . Treatment was ceased because a`toxic delirium' occurred in three cases,`instable (sic) blood pressure, sweating and tremor' in four other cases and in a further three`gross tremor and hyperthermia'. Although the 22% incidence of severe side-effects mandating cessation of treatment is high, it is noteworthy that there was no mortality in this series. This may be attributable to the low maximum dose of only 20 mg of TCP.
Serotonin syndrome and neuroleptic malignant syndrome: di¡erential diagnosis
The differential diagnosis between SS and NMS (see Table 1 ) has caused dif®culties in a few reported cases (Brennan et al., 1988; Kline et al., 1989; Staufenberg and Tantum, 1989; Stern et al., 1992; Ames and Wirshing, 1993; Graber et al., 1994) . These dif®culties have arisen partly because some patients were taking neuroleptics, which seems to have in¯uenced the exclusion of a diagnosis of SS. A presumptive diagnosis of NMS was thus made when the clinical picture indicated SS. In one patient (already on regular chlorpromazine), the dose of chlorpromazine had just been reduced before symptoms developed and it is possible that the protective effect of 5-HT receptor blockade, thus lessened, allowed symptoms to emerge (Staufenberg and Tantum, 1989) . Features differentiating between SS and NMS (Rosebush and Stewart, 1989; Rosenberg and Green, 1989; Caroff and Mann, 1993; Persing, 1994) may be: NMS, slow onset (days to weeks) and slow progression over 24±72 h in association with neuroleptics versus SS, both rapid onset and rapid progression (minutes to hours) in association with a combination of serotonergic drugs; NMS, bradykinesia and lead pipe rigidity versus SS, hyperkinesia and clonus; and NMS, an idiosyncratic reaction to therapeutic dosages versus SS, a manifestation of toxicity (usually to a combination of drugs) to which everyone is liable.
In summary, the precipitating drug de®nes the syndrome: dopamine (DA) receptor blockers produce bradykinesia whereas serotonergic drugs produce hyperkinesia.
Treatment
Many treatments for SS have been described including the 5-HT 2 blockers, methysergide (Sandyk, 1986) and cyproheptadine (see Table 2 ) (Goldberg and Huk, 1992; Beasley et al., 1993; Muly et al., 1993; Lappin and Auchincloss, 1994; Klysner et al., 1995; George and Godleski, 1996) , and the 5-HT 1A blocker propranolol (Rivers and Horner, 1970; Guze and Baxter, 1986; Klee and Kronig, 1993; Lappin and Auchincloss, 1994; Ruiz, 1994; Heisler et al., 1996; Gillman, 1997b) . Various benzodiazepines have been used (Halman and Goldblum, 1990; Ooi, 1991; Lejoyeux et al., 1992; Nierenberg and Semprebon, 1993; Brannan et al., 1994; Graber et al., 1994; Ruiz, 1994; Skop et al., 1994; Baetz and Malcolm, 1995; Reeves and Bullen, 1995; Hodgman et al., 1997) as well as nitroglycerine (Brown and Skop, 1996) , and chlormethiazole (Bedford-Russel et al., 1992) . Neuroleptics have been used, mostly chlorpromazine as reviewed herein (see Table 2 ), but also chlorprothixene (Morch, 1962) and haloperidol, unsuccessfully (Bedford-Russel et al., 1992) .
The relative potency for blockade of 5-HT 2A receptors by various drugs is given in Table 3 (Wander et al., 1987; Richelson, 1996; Richelson et al., 1997) . Chlorprothixene and sertindole are the most potent blockers closely followed by risperidone. Chlorpromazine and cyproheptadine are of similar, but lesser, potency and haloperidol has a low af®nity. All these drugs show af®nities at 5-HT 1A receptors two to three orders of magnitude less (Wander et al., 1987) . This author's initial use of chlorpromazine for SS (Gillman, 1997b) was prompted following the failure of 16 mg of cyproheptadine (orally), which was the biggest dose then reported (Goldberg and Huk, 1992; Beasley et al., 1993; Lappin and Auchincloss, 1994) . The receptor af®nity data (see Table 3 ) accords well with the limited clinical experience in these reports, i.e. the successful use of chlorpromazine, chlorprothixene and cyproheptadine and the apparent failure of haloperidol (BedfordRussel et al., 1992) .
There seems to be concern that chlorpromazine would aggravate seizures by lowering the seizure threshold. Little has been cited to support this and none of the work reviewed here contains evidence for this. Espelin used chlorpromazine to treat hyperpyrexia following amphetamine intoxication, which presents a similar picture, and speci®cally stated that it helped to normalize the electroencephalogram (Espelin and Done, 1968). Green also noted there was concern that neuroleptics caused NMS and could aggravate hyperthermia by lowering DA (Green et al., 1995) . However, the hyperthermia of NMS is an idiosyncratic response to neuroleptics; the normal response is hypothermia. Indeed there is evidence that normal DA activity is needed for the expression of SS (Green and Grahame-Smith, 1974) , thus lowering DA may help to ameliorate it (Marley and Wozniak, 1985) . Chlorpromazine might cause problems by lowering the blood pressure and would be expected to worsen the clinical state if NMS is confused with SS; it should also be noted that bromocriptine, which has frequently been used to treat NMS, has been reported to increase brain 5-HT levels (Snider et al., 1975) with the attendant risk that this could worsen SS (Gillman, 1997a) when it is confused with NMS. An example of such a case may be that of Kline et al. (1989) where treatment with dantrolene and bromocryptine was given to a patient with SS and the temperature then rose from 38.1 8C to 42.2 8C within 3 h and death ensued.
When considering whether drug treatment is required it should be noted the earliest studies indicated that in animal models barbiturate anaesthesia and paralysis reduced body temperature (Himwich, 1962) . An example of the successful use of anaesthesia, paralysis and active cooling is the report of Peebles-Brown (Peebles-Brown, 1985) . A recent review of rapid cooling techniques is that of Harker and Gibson (1995) . However, hyperactivity is not the main cause of hyperthermia (Green et al., 1995) so these measures alone may not be suf®cient.
Analysis of the cases in this review suggests a reasonable starting dose for treatment with chlorpromazine would be 50 mg by IM injection. Larger doses were used in some cases (150 mg by IM injection over 2 h). In Brodribb's case (Brodribb et al., 1994) , 100 mg by IM injection was given twice in 6 h with a further ®ve doses of 100 mg every 6 h (orally) until discharge (Brodribb, personal communication) . In severe cases it is probably reasonable to use an initial dosage of 50±100 mg by I M injection. Cyproheptadine is only available in tablet form. It can be crushed and given via a naso-gastric tube. Doses of 4±16 mg, used in reported cases, may be too low for optimum bene®t; Kapur's recent data using Wander et al. (1987) , Richelson (1996) , Richelson et al. (1997). positron emission tomography indicate that about 30 mg is needed (as a single oral dose) to achieve 85±95% blockade of brain 5-HT 2A receptors (Kapur et al., 1997) . This is supported by one of this author's cases where 16 mg of cyproheptadine failed to provide any amelioration of symptoms in a moderately severe case, whereas chlorpromazine 50 mg IM was followed by resolution of symptoms in 2 h (Gillman, 1997b) . The evidence for the clinical effectiveness of chlorpromazine and cyproheptadine in human cases of SS is somewhat unsatisfactory because it is based on post hoc analysis of case reports. However, it is supported by extensive data from animal work that clari®es the role of 5-HT. More work is needed, especially to elucidate the extent to which various combinations of drugs raise intra-synaptic 5-HT, which is probably the most important factor determining severity.
Rapid deterioration over 2±4 h is well documented in many recent reports (Beasley et al., 1993; Brodribb et al., 1994; Graber et al., 1994; Corkeron, 1995; Brubacher et al., 1996; George and Godleski, 1996; Gillman, 1996; Mathew et al., 1996) which suggests a conservative approach to treatment may not always be justi®ed, especially when potent and long acting drugs are implicated, e.g. non-speci®c MAOIs (TCP and phenelzine) with serotonin reuptake inhibitors like CMI and uoxetine. Even RIMAs like MOC (in overdose) have been involved in cases exhibiting rapid deterioration or death (Brodribb et al., 1994; Hernandez et al., 1995; Kuisma, 1995; Power et al., 1995; Francois et al., 1997) .
Conclusions
SS is a potentially serious condition that can worsen rapidly. Paralysis and active cooling may not be suf®cient treatment in severe cases; these may require 5-HT 2 blocking drugs as a life saving measure. The evidence suggests that cyproheptadine and chlorpromazine may be effective. In milder cases, these drugs can provide relief of distressing symptoms. Consideration of the factors discussed in this review may aid in balancing the risks and bene®ts of active intervention with drugs. Where the diagnosis is uncertain, and NMS is a possibility, it may be advisable to avoid both bromocriptine and chlorpromazine. In such cases, paralysis and rapid cooling, and/or cyproheptadine, may prevent the development of disseminated intravascular coagulation and other complications, which can be fatal. 
